Krieger J, Racineux J L, Huber P, Sautegeau A, Redondo J, Castaing Y, Lévy P
Bull Eur Physiopathol Respir. 1986 Jul-Aug;22(4):393-7.
The efficacy and tolerance of a nasal CPAP device marketed in France (Pression +, Sefam) for the treatment of obstructive sleep apnoea syndromes have been evaluated in a co-operative trial including 12 patients. This study confirmed the efficacy of nasal CPAP on sleep parameters: total sleep time was increased; light non-REM sleep was diminished; slow-wave sleep and REM sleep were augmented; sleep apnoeas were eliminated completely or almost completely; oxygen saturation was markedly improved. At one month follow-up, most clinical features were improved; daytime blood gases showed little change but the number of red cells was decreased. On the whole, the tolerance was good in this highly motivated group of patients: eleven patients (92%) were willing to continue their home treatment with the same device. Most difficulties were due to the making of a tailored molded nasal mask and its use during sleep.
在一项纳入12例患者的合作试验中，对法国市场上销售的一种用于治疗阻塞性睡眠呼吸暂停综合征的鼻持续气道正压通气（CPAP）设备（Pression +，Sefam）的疗效和耐受性进行了评估。该研究证实了鼻CPAP对睡眠参数的疗效：总睡眠时间增加；浅度非快速眼动睡眠减少；慢波睡眠和快速眼动睡眠增加；睡眠呼吸暂停完全或几乎完全消除；血氧饱和度显著改善。在1个月的随访中，大多数临床特征得到改善；白天血气变化不大，但红细胞数量减少。总体而言，在这群积极性很高的患者中耐受性良好：11例患者（92%）愿意继续使用同一设备进行家庭治疗。大多数困难在于制作定制的塑形鼻罩及其在睡眠期间的使用。
